NO20010490D0 - Inhibisjon av ''graft-versus-host''-sykdom - Google Patents

Inhibisjon av ''graft-versus-host''-sykdom

Info

Publication number
NO20010490D0
NO20010490D0 NO20010490A NO20010490A NO20010490D0 NO 20010490 D0 NO20010490 D0 NO 20010490D0 NO 20010490 A NO20010490 A NO 20010490A NO 20010490 A NO20010490 A NO 20010490A NO 20010490 D0 NO20010490 D0 NO 20010490D0
Authority
NO
Norway
Prior art keywords
graft
versus
inhibition
host
disease
Prior art date
Application number
NO20010490A
Other languages
English (en)
Other versions
NO20010490L (no
Inventor
David Elliott Spaner
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of NO20010490D0 publication Critical patent/NO20010490D0/no
Publication of NO20010490L publication Critical patent/NO20010490L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
NO20010490A 1998-07-30 2001-01-29 Inhibisjon av ''graft-versus-host''-sykdom NO20010490L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2244554 CA2244554A1 (en) 1998-07-30 1998-07-30 Inhibition of graft versus host disease
PCT/CA1999/000706 WO2000006703A2 (en) 1998-07-30 1999-07-30 Inhibition of graft versus host disease

Publications (2)

Publication Number Publication Date
NO20010490D0 true NO20010490D0 (no) 2001-01-29
NO20010490L NO20010490L (no) 2001-03-29

Family

ID=4162727

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010490A NO20010490L (no) 1998-07-30 2001-01-29 Inhibisjon av ''graft-versus-host''-sykdom

Country Status (16)

Country Link
US (2) US6258357B1 (no)
EP (1) EP1100875A2 (no)
JP (1) JP2002523332A (no)
KR (1) KR20010072095A (no)
CN (1) CN1314939A (no)
AU (1) AU755630B2 (no)
BR (1) BR9912594A (no)
CA (1) CA2244554A1 (no)
CZ (1) CZ2001316A3 (no)
EA (1) EA200100195A1 (no)
IL (1) IL141007A0 (no)
MX (1) MXPA01001144A (no)
NO (1) NO20010490L (no)
NZ (1) NZ509387A (no)
WO (1) WO2000006703A2 (no)
ZA (1) ZA200101614B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE516133C2 (sv) * 1999-02-25 2001-11-19 Lundblad Leif J I Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
CA2324199A1 (en) * 2000-10-25 2002-04-25 Vasogen Ireland Limited Chronic lymphocytic leukemia treatment
HUP0402360A2 (hu) * 2001-07-31 2005-02-28 Anormed Inc. Poliaminok alkalmazása progenitor sejtek és/vagy őssejtek számának növelésére alkalmas gyógyszerkészítmény előállítására
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
ES2422193T3 (es) * 2002-06-28 2013-09-09 Life Technologies Corp Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US7189694B2 (en) * 2003-04-18 2007-03-13 University Of Florida Research Foundation, Inc. Inhibitors of autophosphorylation protein kinases
US20090232834A1 (en) * 2005-07-18 2009-09-17 Al-Harbi Saleh A Methods and Agents to Treat Autoimmune Diseases
WO2008128069A1 (en) * 2007-04-11 2008-10-23 Roger Deutsch Methods for diagnosing biological samples containing stem cells
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
CA2743697A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2612907A1 (en) * 2012-01-05 2013-07-10 Taipei Veterans General Hospital Preparation of cell transplant
RU2508924C1 (ru) * 2013-02-21 2014-03-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения отторжения почечного трансплантата
JP7445946B2 (ja) * 2019-06-12 2024-03-08 国立大学法人九州大学 性質変化方法及びプラズマ生成装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2220971A1 (en) 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
EP0797967B1 (en) * 1996-03-29 2000-08-23 The Procter & Gamble Company Method for assessing disposable absorbent structures

Also Published As

Publication number Publication date
CA2244554A1 (en) 2000-01-30
WO2000006703A2 (en) 2000-02-10
NZ509387A (en) 2002-10-25
WO2000006703A3 (en) 2000-05-04
NO20010490L (no) 2001-03-29
ZA200101614B (en) 2002-01-02
US20010028879A1 (en) 2001-10-11
EP1100875A2 (en) 2001-05-23
JP2002523332A (ja) 2002-07-30
CZ2001316A3 (cs) 2001-10-17
AU5143399A (en) 2000-02-21
KR20010072095A (ko) 2001-07-31
MXPA01001144A (es) 2002-04-24
IL141007A0 (en) 2002-02-10
US6258357B1 (en) 2001-07-10
EA200100195A1 (ru) 2001-10-22
BR9912594A (pt) 2002-04-23
AU755630B2 (en) 2002-12-19
CN1314939A (zh) 2001-09-26

Similar Documents

Publication Publication Date Title
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
FR20C1039I2 (fr) Derives de l'uk-2a
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
DE60023268D1 (de) INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
DZ2495A1 (fr) Formule nouvelle de l'oméprazole-s.
NO20002686D0 (no) Forbedring av Peyronies sykdom
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
IL149592A0 (en) Synthesis of 2'-deoxy-l-nucleosides
NO20010490D0 (no) Inhibisjon av ''graft-versus-host''-sykdom
NO981388D0 (no) Bedring av Dupuytrens sykdom
NO20010651D0 (no) Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenase
FR2779192B1 (fr) Accouplement d'arbres
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
TR199701051A3 (tr) 2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi
FR2784283B1 (fr) Clou medullaire d'osteosynthese
FR2802852B3 (fr) Production d'elements figures
NO20016030L (no) Derivater av 4'-demykarosyl-8a-aza-8a-homotylosin
ATE243218T1 (de) 2''-deoxyhygromycinderivate
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
ITMI20000810A0 (it) Procedimento per la preparazione di 5'-acetilstavudina
FR2810389B1 (fr) Raccordement d'embouts
UA1629S (uk) Набір фестонів "веснянка-5"
UA2593S (uk) Комплект етикеток для гіркої настоянки "град чернігів"
UA2190S (uk) Комплект етикеток "древньокиївська"

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application